{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T20:23:22Z","timestamp":1773865402345,"version":"3.50.1"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["jgaronline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.jgar.2016.08.013","type":"journal-article","created":{"date-parts":[[2016,11,2]],"date-time":"2016-11-02T16:00:19Z","timestamp":1478102419000},"page":"28-32","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Prevalence of macrolide\u2013lincosamide resistance and multidrug resistance phenotypes in streptococcal isolates causing infections in European hospitals: Evaluation of the in vitro activity of oritavancin and comparator agents"],"prefix":"10.1016","volume":"8","author":[{"given":"Rodrigo E.","family":"Mendes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariana","family":"Castanheira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J.","family":"Farrell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert K.","family":"Flamm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helio S.","family":"Sader","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald N.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2016.08.013_bib0005","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1086\/599369","article-title":"Increasing burden of invasive group B streptococcal disease in nonpregnant adults, 1990\u20132007","volume":"49","author":"Skoff","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2016.08.013_bib0010","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1128\/JCM.01128-15","article-title":"Emergence of serotype IV group B Streptococcus adult invasive disease in Manitoba and Saskatchewan, Canada, is driven by clonal sequence type 459 strains","volume":"53","author":"Teatero","year":"2015","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jgar.2016.08.013_bib0015","doi-asserted-by":"crossref","first-page":"O216","DOI":"10.1111\/1469-0691.12378","article-title":"Nationwide laboratory-based surveillance of invasive beta-haemolytic streptococci in Denmark from 2005 to 2011","volume":"20","author":"Lambertsen","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jgar.2016.08.013_bib0020","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S1473-3099(05)70267-X","article-title":"The global burden of group A streptococcal diseases","volume":"5","author":"Carapetis","year":"2005","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jgar.2016.08.013_bib0025","series-title":"Active Bacterial Core surveillance (ABCs) report. Emerging infections program network. Group B","author":"US Centers for Disease Control and Prevention","year":"2013"},{"key":"10.1016\/j.jgar.2016.08.013_bib0030","series-title":"Active Bacterial Core surveillance (ABCs) report. Emerging infections program network. Group A","author":"US Centers for Disease Control and Prevention","year":"2013"},{"key":"10.1016\/j.jgar.2016.08.013_bib0035","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1093\/cid\/cit337","article-title":"Emerging trends in the epidemiology of invasive group B streptococcal disease in England and Wales, 1991\u20132010","volume":"57","author":"Lamagni","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2016.08.013_bib0040","doi-asserted-by":"crossref","first-page":"E545","DOI":"10.1111\/1469-0691.12276","article-title":"Necrotizing soft tissue infections caused by Streptococcus pyogenes and Streptococcus dysgalactiae subsp. equisimilis of groups C and G in western Norway","volume":"19","author":"Bruun","year":"2013","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jgar.2016.08.013_bib0045","doi-asserted-by":"crossref","first-page":"20443","DOI":"10.2807\/1560-7917.ES2013.18.14.20443","article-title":"Increased incidence of invasive group A streptococcal infections in Sweden, January 2012\u2013February 2013","volume":"18","author":"Darenberg","year":"2013","journal-title":"Euro Surveill"},{"key":"10.1016\/j.jgar.2016.08.013_bib0050","doi-asserted-by":"crossref","first-page":"20749","DOI":"10.2807\/1560-7917.ES2014.19.12.20749","article-title":"Increase in scarlet fever notifications in the United Kingdom, 2013\/2014","volume":"19","author":"Guy","year":"2014","journal-title":"Euro Surveill"},{"key":"10.1016\/j.jgar.2016.08.013_bib0055","series-title":"Manual of clinical microbiology","author":"Murray","year":"2007"},{"key":"10.1016\/j.jgar.2016.08.013_bib0060","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/BF01690091","article-title":"Seven-year review of bacteremia caused by Streptococcus milleri and other viridans streptococci","volume":"15","author":"Salavert","year":"1996","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2016.08.013_bib0065","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1093\/jac\/dkt541","article-title":"Zyvox\u00ae Annual Appraisal of Potency and Spectrum (ZAAPS) program: report of linezolid activity over nine years (2004\u20132012)","volume":"69","author":"Mendes","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2016.08.013_bib0070","first-page":"67","article-title":"Endocarditis caused by nutritionally variant streptococci: a case report and literature review","volume":"20","author":"Giuliano","year":"2012","journal-title":"Infez Med"},{"key":"10.1016\/j.jgar.2016.08.013_bib0075","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1128\/JCM.00757-13","article-title":"Streptococcus sanguinis isolates displaying a phenotype with cross-resistance to several rRNA-targeting agents","volume":"51","author":"Mendes","year":"2013","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jgar.2016.08.013_bib0080","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1128\/AAC.04219-14","article-title":"Characterization of high-level daptomycin resistance in viridans group streptococci developed upon in vitro exposure to daptomycin","volume":"59","author":"Akins","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2016.08.013_bib0085","doi-asserted-by":"crossref","first-page":"e01386","DOI":"10.1128\/mBio.01386-14","article-title":"vanG element insertions within a conserved chromosomal site conferring vancomycin resistance to Streptococcus agalactiae and Streptococcus anginosus","volume":"5","author":"Srinivasan","year":"2014","journal-title":"mBio"},{"key":"10.1016\/j.jgar.2016.08.013_bib0090","series-title":"ORBACTIV\u2122 package insert 2016","author":"The Medicines Company","year":"2014"},{"key":"10.1016\/j.jgar.2016.08.013_bib0095","series-title":"Orbactiv summary of product characteristics (Annex I)","author":"European Medicines Agency","year":"2015"},{"key":"10.1016\/j.jgar.2016.08.013_bib0100","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1093\/jac\/dku421","article-title":"Activity of oritavancin against Gram-positive clinical isolates responsible for documented skin and soft-tissue infections in European and US hospitals (2010\u20132013)","volume":"70","author":"Mendes","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2016.08.013_bib0105","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1093\/jac\/dku016","article-title":"Activity of oritavancin tested against uncommonly isolated Gram-positive pathogens responsible for documented infections in hospitals worldwide","volume":"69","author":"Mendes","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2016.08.013_bib0110","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.ijantimicag.2015.08.014","article-title":"In vitro activity of oritavancin and comparator agents against staphylococci, streptococci and enterococci from clinical infections in Europe and North America, 2011\u20132014","volume":"46","author":"Biedenbach","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2016.08.013_bib0115","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.diagmicrobio.2014.09.003","article-title":"In vitro activity of oritavancin against Gram-positive pathogens isolated in Canadian hospital laboratories from 2011\u20132013","volume":"80","author":"Karlowsky","year":"2014","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2016.08.013_bib0120","series-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard","author":"Clinical and Laboratory Standards Institute","year":"2015"},{"key":"10.1016\/j.jgar.2016.08.013_bib0125","series-title":"Performance standards for antimicrobial susceptibility testing; twenty-fifth informational supplement","author":"Clinical and Laboratory Standards Institute","year":"2015"},{"key":"10.1016\/j.jgar.2016.08.013_bib0130","series-title":"Breakpoint tables for interpretation of MICs and zone diameters. Version 5.0","author":"European Committee on Antimicrobial Susceptibility Testing","year":"2015"},{"key":"10.1016\/j.jgar.2016.08.013_bib0135","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/j.1574-6968.2008.01145.x","article-title":"Update on macrolide\u2013lincosamide\u2013streptogramin, ketolide, and oxazolidinone resistance genes","volume":"28","author":"Roberts","year":"2008","journal-title":"FEMS Microbiol Lett"},{"key":"10.1016\/j.jgar.2016.08.013_bib0140","first-page":"106","article-title":"First clinical isolate in Europe of clindamycin-resistant group B Streptococcus mediated by the lnu(B) gene","volume":"27","author":"Arana","year":"2014","journal-title":"Rev Esp Quimioter"},{"key":"10.1016\/j.jgar.2016.08.013_bib0145","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1093\/jac\/dkv182","article-title":"Declining macrolide resistance in Streptococcus pyogenes in Portugal (2007\u201313) was accompanied by continuous clonal changes","volume":"70","author":"Silva-Costa","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2016.08.013_bib0150","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1093\/jac\/dkq230","article-title":"Population structure, virulence factors and resistance determinants of invasive, non-invasive and colonizing Streptococcus agalactiae in Poland","volume":"65","author":"Sadowy","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2016.08.013_bib0155","doi-asserted-by":"crossref","first-page":"e01139","DOI":"10.1128\/genomeA.01139-15","article-title":"Draft genome sequences of four genetically distinct human isolates of Streptococcus dysgalactiae subsp. equisimilis","volume":"3","author":"Evers","year":"2015","journal-title":"Genome Announc"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221371651630114X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221371651630114X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,6]],"date-time":"2018-09-06T21:27:02Z","timestamp":1536269222000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221371651630114X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":31,"alternative-id":["S221371651630114X"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2016.08.013","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prevalence of macrolide\u2013lincosamide resistance and multidrug resistance phenotypes in streptococcal isolates causing infections in European hospitals: Evaluation of the in vitro activity of oritavancin and comparator agents","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2016.08.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 International Society for Chemotherapy of Infection and Cancer. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}